PharVision Advisers’s Progyny PGNY Stock Holding History

PharVision Advisers’s Portfolio PGNY Stock Details PGNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,681	Closed	-$300K	–	505
2025 Q4	$300K	Sell	11,681 -9,144	-44%	-$210K	0.15%	269
2025 Q3	$448K	Buy	+20,825	New	+$473K	0.25%	42

Other funds holding PGNY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

PharVision Advisers's PGNY Position: Q1 2026 in Review

PharVision Advisers sold out of Progyny (PGNY) in Q1 2026, closing a stake of 11,681 shares — an estimated $300K sold.

PharVision Advisers first reported a position in PGNY in Q3 2025 and held it in 2 quarters. The position peaked at $448K in Q3 2025. 291 funds tracked by Wall St. Rank hold PGNY as of Q1 2026.

PharVision Advisers reported no remaining Progyny position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 11,681 Progyny shares in Q1 2026, an estimated $300K.
PharVision Advisers first reported a position in Progyny in Q3 2025 and held it in 2 quarters.
PharVision Advisers's Progyny position peaked at $448K in Q3 2025.
291 funds tracked by Wall St. Rank held Progyny as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.